The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Pamidronate to Prevent Bone Loss during Androgen-Deprivation Therapy for Prostate Cancer
Open accessAbstract
BACKGROUND: Treatment with a gonadotropin-releasing hormone agonist decreases bone mineral density and increases the risk of fracture in men with prostate cancer. We conducted a controlled study of the prevention of osteoporosis in men undergoing treatment with a gonadotropin-releasing hormone agonist. METHODS: In a 48-week, open-label study, we randomly assigned 47 men with advanced or recurrent prostate cancer and no bone metastases to receive either leuprolide alone or leuprolide and pamidronate (60 mg intravenously every 12 weeks). Bone mineral density of the lumbar spine and the proximal femur was measured by dual-energy x-ray absorptiometry. Trabecular bone mineral density of the lumbar spine was measured by quantitative computed tomography. Forty-one men completed the study. RESULTS: In men treated with leuprolide alone, the mean (+/-SE) bone mineral density decreased by 3.3+/-0.7 percent in the lumbar spine, 2.1+/-0.6 percent in the trochanter, and 1.8+/-0.4 percent in the total hip, and the mean trabecular bone mineral density of the lumbar spine decreased by 8.5+/-1.8 percent (P<0.001 for each comparison with the base-line value). In contrast, the mean bone mineral density did not change significantly at any skeletal site in men treated with both leuprolide and pamidronate. There were significant differences between the two groups in the mean changes in bone mineral density at 48 weeks in the lumbar spine (P<0.001), trochanter (P = 0.003), total hip (P=0.005), and trabecular bone of the lumbar spine (P=0.02). CONCLUSIONS: Pamidronate prevents bone loss in the hip and lumbar spine in men receiving treatment for prostate cancer with a gonadotropin-releasing hormone agonist.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fundamentals of Biostatistics.
(1969) · Annals of Internal Medicine · doi:10.7326/0003-4819-70-4-873 · Cited by 4,575
Greenlee, R. T., Hill-Harmon, M. B., Murray, T., & Thun, M. (2001) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.51.1.15 · Cited by 3,288
Bolla, M., Gonzalez, D., Warde, P., Dubois, J. B., Mirimanoff, R.-O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., Gil, T., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707313370502 · Cited by 1,548
Messing, E. M., Manola, J., Sarosdy, M., Wilding, G., Crawford, E. D., & Trump, D. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912093412401 · Cited by 1,191
Cummings, S. R. (1990) · JAMA · doi:10.1001/jama.263.5.665 · Cited by 1,011
Alendronate for the Treatment of Osteoporosis in Men
Orwoll, E., Ettinger, M., Weiss, S., Miller, P., Kendler, D., Graham, J., Adami, S., Weber, K., Lorenc, R., Pietschmann, P., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008313430902 · Cited by 973
Katznelson, L., Finkelstein, J. S., Schoenfeld, D. A., Rosenthal, D. I., Anderson, E. J., & Klibanski, A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.12.8954042 · Cited by 791
Self-citation(1997) · British Journal of Urology · doi:10.1046/j.1464-410x.1997.d01-6840.x · Cited by 654
Cited by
Noninvasive detection of clinically occult lymph-node metastases in prostate cancer
Harisinghani, M. G., Barentsz, J., Hahn, P. F., Deserno, W. M., Tabatabaei, S., van de Kaa, C. H., de la Rosette, J., & Weissleder, R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022749 · Cited by 1,971
Saad, F., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., Chin, J. L., Vinholes, J. J., Goas, J. A., & Chen, B. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.19.1458 · Cited by 1,656
Bisphosphonates: Mechanism of action and role in clinical practice
Drake, M. T., Clarke, B. L., & Khosla, S. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.9.1032 · Cited by 1,644
Risk of Fracture after Androgen Deprivation for Prostate Cancer
Shahinian, V. B., Kuo, Y.-F., Freeman, J. L., & Goodwin, J. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041943 · Cited by 1,375
Denosumab in men receiving androgen-deprivation therapy for prostate cancer
Smith, M. R., Egerdie, B., Toriz, N. H., Feldman, R., Tammela, T. L. J., Saad, F., Heracek, J., Szwedowski, M., Ke, C., Kupic, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809003 · Cited by 1,140
Self-citationAndrogen Deprivation Therapy for Prostate Cancer
Sharifi, N. (2005) · JAMA · doi:10.1001/jama.294.2.238 · Cited by 1,083
American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 2010
Wolf, A. M. D., Wender, R. C., Etzioni, R. B., Thompson, I. M., D'Amico, A. V., Volk, R. J., Brooks, D. D., Dash, C., Guessous, I., Andrews, K., et al. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20066 · Cited by 965
Mohler, J., Bahnson, R. R., Boston, B., Busby, J. E., D'Amico, A., Eastham, J. A., Enke, C. A., George, D., Horwitz, E. M., Huben, R. P., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0012 · Cited by 897
Self-citationAdverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them
Nguyen, P. L., Alibhai, S. M. H., Basaria, S., D’Amico, A. V., Kantoff, P. W., Keating, N. L., Penson, D. F., Rosario, D. J., Tombal, B., & Smith, M. R. (2015) · European Urology · doi:10.1016/j.eururo.2014.07.010 · Cited by 831
Self-citationGonadal Steroids and Body Composition, Strength, and Sexual Function in Men
Finkelstein, J. S., Lee, H., Burnett-Bowie, S.-A. M., Pallais, J. C., Yu, E. W., Borges, L. F., Jones, B. F., Barry, C. V., Wulczyn, K. E., Thomas, B. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1206168 · Cited by 782
Self-citationVanderschueren, D., Vandenput, L., Boonen, S., Lindberg, M. K., Bouillon, R., & Ohlsson, C. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0003 · Cited by 717
Changes in body composition during androgen deprivation therapy for prostate cancer
Smith, M. R., Finkelstein, J. S., McGovern, F. J., Zietman, A. L., Fallon, M. A., Schoenfeld, D. A., & Kantoff, P. W. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8299 · Cited by 697
Self-citationSMITH, M. R., EASTHAM, J., GLEASON, D. M., SHASHA, D., TCHEKMEDYIAN, S., & ZINNER, N. (2003) · Journal of Urology · doi:10.1097/01.ju.0000063820.94994.95 · Cited by 650
Self-citationOsteoporosis in Men: An Endocrine Society Clinical Practice Guideline
Watts, N. B., Adler, R. A., Bilezikian, J. P., Drake, M. T., Eastell, R., Orwoll, E. S., & Finkelstein, J. S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3045 · Cited by 611
Self-citationReview of Exercise Intervention Studies in Cancer Patients
Galvão, D. A., & Newton, R. U. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.085 · Cited by 578
Bone health in cancer patients: ESMO Clinical Practice Guidelines
Coleman, R., Body, J. J., Aapro, M., Hadji, P., & Herrstedt, J. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu103 · Cited by 564
Basic Mechanisms Responsible for Osteolytic and Osteoblastic Bone Metastases
Guise, T. A., Mohammad, K. S., Clines, G., Stebbins, E. G., Wong, D. H., Higgins, L. S., Vessella, R., Corey, E., Padalecki, S., Suva, L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1007 · Cited by 539
Bone metastasis: the importance of the neighbourhood
Croucher, P. I., McDonald, M. M., & Martin, T. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.44 · Cited by 479
Aapro, M., Abrahamsson, P. A., Body, J. J., Coleman, R. E., Colomer, R., Costa, L., Crinò, L., Dirix, L., Gnant, M., Gralow, J., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm442 · Cited by 457
Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone
Kobayashi, A., Okuda, H., Xing, F., Pandey, P. R., Watabe, M., Hirota, S., Pai, S. K., Liu, W., Fukuda, K., Chambers, C., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110840 · Cited by 427
NCCN Task Force Report: Bone Health in Cancer Care
Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., Kumar, R., Litsas, G., McKay, R., Podoloff, D. A., Srinivas, S., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0215 · Cited by 412
Hypogonadism in men consuming sustained-action oral opioids
Daniell, H. W. (2002) · The Journal of Pain · doi:10.1054/jpai.2002.126790 · Cited by 401
The Current State of Hormonal Therapy for Prostate Cancer
Hellerstedt, B. A., & Pienta, K. J. (2002) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.52.3.154 · Cited by 386
Mechanisms of sex steroid effects on bone
Syed, F., & Khosla, S. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.11.097 · Cited by 380
Smith, M. R., Lee, W. C., Brandman, J., Wang, Q., Botteman, M., & Pashos, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.6908 · Cited by 366
Self-citationLong‐term effects of androgen deprivation therapy in prostate cancer patients
Basaria, S., Lieb, J., Tang, A. M., DeWeese, T., Carducci, M., Eisenberger, M., & Dobs, A. S. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01551.x · Cited by 359
Michaelson, M. D., Kaufman, D. S., Lee, H., McGovern, F. J., Kantoff, P. W., Fallon, M. A., Finkelstein, J. S., & Smith, M. R. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3361 · Cited by 330
Self-citationReview of major adverse effects of androgen‐deprivation therapy in men with prostate cancer
Taylor, L. G., Canfield, S. E., & Du, X. L. (2009) · Cancer · doi:10.1002/cncr.24283 · Cited by 324
BERRUTI, A., DOGLIOTTI, L., TERRONE, C., CERUTTI, S., ISAIA, G., TARABUZZI, R., REIMONDO, G., MARI, M., ARDISSONE, P., DE LUCA, S., et al. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64985-3 · Cited by 315
Greenspan, S. L., Nelson, J. B., Trump, D. L., & Resnick, N. M. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-6-200703200-00006 · Cited by 302
Management of the adverse effects associated with intravenous bisphosphonates
Tanvetyanon, T., & Stiff, P. J. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj105 · Cited by 301
Resistance Training and Reduction of Treatment Side Effects in Prostate Cancer Patients
GALVÃO, D. A., NOSAKA, K., TAAFFE, D. R., SPRY, N., KRISTJANSON, L. J., MCGUIGAN, M. R., SUZUKI, K., YAMAYA, K., & NEWTON, R. U. (2006) · Medicine & Science in Sports & Exercise · doi:10.1249/01.mss.0000233803.48691.8b · Cited by 297
Differential Effects of Androgens and Estrogens on Bone Turnover in Normal Men
Leder, B. Z., LeBlanc, K. M., Schoenfeld, D. A., Eastell, R., & Finkelstein, J. S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021036 · Cited by 283
Self-citationBone Loss following Hypogonadism in Men with Prostate Cancer Treated with GnRH Analogs
Mittan, D. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.8.3656 · Cited by 278
Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer
MCLEOD, D. G., IVERSEN, P., SEE, W. A., MORRIS, T., ARMSTRONG, J., WIRTH, M. P., & the Casodex Early Prostate Cancer Trialists’ Group (2006) · BJU International · doi:10.1111/j.1464-410x.2005.06051.x · Cited by 277
Current therapy and drug resistance in metastatic castration-resistant prostate cancer
Cai, M., Song, X.-L., Li, X.-A., Chen, M., Guo, J., Yang, D.-H., Chen, Z., & Zhao, S.-C. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.100962 · Cited by 262
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
He, Y., Xu, W., Xiao, Y.-T., Huang, H., Gu, D., & Ren, S. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01042-7 · Cited by 261
Diamond, T. H., Higano, C. S., Smith, M. R., Guise, T. A., & Singer, F. R. (2004) · Cancer · doi:10.1002/cncr.20056 · Cited by 255
Self-citationGonadal steroid–dependent effects on bone turnover and bone mineral density in men
Finkelstein, J. S., Lee, H., Leder, B. Z., Burnett-Bowie, S.-A. M., Goldstein, D. W., Hahn, C. W., Hirsch, S. C., Linker, A., Perros, N., Servais, A. B., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84137 · Cited by 198
Self-citationManagement of Complications of Prostate Cancer Treatment
Michaelson, M. D., Cotter, S. E., Gargollo, P. C., Zietman, A. L., Dahl, D. M., & Smith, M. R. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2008.0002 · Cited by 196
Self-citationSmith, M. R., Goode, M., Zietman, A. L., McGovern, F. J., Lee, H., & Finkelstein, J. S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.174 · Cited by 188
Self-citationAlibhai, S. M. H., Gogov, S., & Allibhai, Z. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.06.006 · Cited by 173
Golds, G., Houdek, D., & Arnason, T. (2017) · International Journal of Endocrinology · doi:10.1155/2017/4602129 · Cited by 150
Andropause: Symptom Management for Prostate Cancer Patients Treated With Hormonal Ablation
Thompson, C. A., Shanafelt, T. D., & Loprinzi, C. L. (2003) · The Oncologist · doi:10.1634/theoncologist.8-5-474 · Cited by 84
Management of side effects of androgen deprivation therapy
Grossmann, M., & Zajac, J. D. (2011) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2011.05.004 · Cited by 69
Saad, F., Shore, N., Van Poppel, H., Rathkopf, D. E., Smith, M. R., de Bono, J. S., Logothetis, C. J., de Souza, P., Fizazi, K., Mulders, P. F. A., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.04.032 · Cited by 63
Self-citationDecreased bone density in men on methadone maintenance therapy
Grey, A., Rix‐Trott, K., Horne, A., Gamble, G., Bolland, M., & Reid, I. R. (2011) · Addiction · doi:10.1111/j.1360-0443.2010.03159.x · Cited by 61
Michaelson, M. D., Marujo, R. M., & Smith, M. R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0735 · Cited by 60
Self-citationPaller, C. J., Shiels, M. S., Rohrmann, S., Basaria, S., Rifai, N., Nelson, W., Platz, E. A., & Dobs, A. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03300.x · Cited by 57
Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men
Leder, B. Z., & Finkelstein, J. S. (2005) · Osteoporosis International · doi:10.1007/s00198-005-1890-8 · Cited by 44
Self-citationTombal, B., Borre, M., Rathenborg, P., Werbrouck, P., Van Poppel, H., Heidenreich, A., Iversen, P., Braeckman, J., Heracek, J., Baron, B., et al. (2018) · Journal of Urology · doi:10.1016/j.juro.2017.08.103 · Cited by 26
Self-citation
Metadata
- Authors
- Smith, M. R., McGovern, F. J., Zietman, A. L., Fallon, M. A., Hayden, D. L., Schoenfeld, D. A., Kantoff, P. W., & Finkelstein, J. S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2001-09-27
- Volume
- 345
- Issue
- 13
- Pages
- 948-955
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2024266959
- Cited by
- 696
- References
- 31
- FWCI
- 20.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.